Related Experiment Video

Updated: Jun 14, 2025

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

11.9K

Efficacy of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors in Non-Ischemic Dilated Cardiomyopathy: A

Jordan Llerena-Velastegui1,2, Melisa Santamaria-Lasso1, Melany Mejia-Mora1

  • 1Medical School, Pontifical Catholic University of Ecuador, Quito, Ecuador.

Cardiology Research
|August 29, 2024
PubMed

Insights

Beta-blockers significantly improve left ventricular ejection fraction in non-ischemic dilated cardiomyopathy (NIDCM) patients. This systematic review recommends beta-blockers as a first-line therapy for NIDCM heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Research

Background:

  • Non-ischemic dilated cardiomyopathy (NIDCM) presents a significant challenge in heart failure management due to poor prognosis and uncertain therapeutic strategies.
  • Optimal treatment for chronic heart failure secondary to NIDCM remains an area requiring further investigation.

Purpose of the Study:

  • To systematically review and assess the efficacy and safety of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors in managing chronic heart failure in NIDCM patients.
  • To explore the potential mechanisms of action for beta-blockers and ACE inhibitors in NIDCM.

Main Methods:

  • A systematic literature review was conducted using PubMed and EMBASE databases, covering studies published between 1990 and 2023.
  • The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on the impact on left ventricular ejection fraction (LVEF).

Main Results:

  • Beta-blockers demonstrated a significant positive effect on LVEF improvement in NIDCM patients (Cohen's d = 1.30), despite high heterogeneity.
  • ACE inhibitors also showed a beneficial role, but with considerably less heterogeneity and a nonsignificant overall effect on LVEF.

Conclusions:

  • The findings highlight the superior efficacy of carvedilol (a beta-blocker) in enhancing LVEF compared to ACE inhibitors in NIDCM.
  • Beta-blockers are recommended as the primary therapeutic approach for NIDCM, with a call for further research into the role of ACE inhibitors.
Abstract

Keywords:
ACE inhibitorsBeta-blockersLeft ventricular ejection fractionMeta-analysisNon-ischemic dilated cardiomyopathySystematic review

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
604
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
544
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421